Update on ropinirole in the treatment of Parkinson’s disease

Holly A Shill, Mark StacySun Health Research Institute, Sun City, AZ, USA; Duke University and Medical Center, Durham, NC, USAAbstract: Ropinirole is a dopamine agonist, approved for use to treat symptoms of early and advanced Parkinson’s disease, is now available in a 24-hour formulat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Holly A Shill, Mark Stacy
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://doaj.org/article/6ffc494fa7e0479cba2849d6edcf70f0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Holly A Shill, Mark StacySun Health Research Institute, Sun City, AZ, USA; Duke University and Medical Center, Durham, NC, USAAbstract: Ropinirole is a dopamine agonist, approved for use to treat symptoms of early and advanced Parkinson’s disease, is now available in a 24-hour formulation in addition to the immediate release version. This review discusses the mode of action of ropinirole and compares the pharmacokinetics of both formulations. Pivotal studies leading to the approval of both preparations are reviewed in terms of efficacy, dose range and side effects. Patient factors such as compliance are discussed in terms of the place for ropinirole in the armamentarium of Parkinson’s disease therapies.Keywords: ropinirole extended release, ropinirole immediate release Parkinson’s disease